Global Professional Diagnostics Market Trends and Insights
Expansion of Molecular and Precision Diagnostics
Molecular diagnostics is becoming a core component of oncology and infectious disease workflows. The FDA approved Guardant360 Liquid CDx in May 2026 as the largest FDA-approved liquid biopsy panel, with a genomic footprint 100 times wider than its predecessor. The platform combines genomic and epigenomic information and includes seven earlier companion diagnostic indications, strengthening treatment selection. Abbott launched its next-generation Oncodetect molecular residual disease test in October 2026, using whole-genome sequencing and MAESTRO technology to track up to 5,000 patient-specific variants. These developments align diagnostic demand with targeted therapy pipelines, which require reliable testing for patient selection and monitoring.Decentralization of Testing to Professional Point-of-Care Sites
Professional testing is expanding into physician office laboratories, urgent care centers, and specialty clinics as compact systems become more practical for ambulatory care. Roche received FDA clearance and a CLIA waiver for cobas liat CT/NG and CT/NG/MG in 2025, extending molecular sexually transmitted infection testing to point-of-care settings. Truvian's FDA-cleared TruVerus analyzer demonstrated that physician offices can perform common blood tests and obtain results within minutes. This shift can redirect testing volumes from central laboratories without reducing demand for professional-grade testing. Suppliers serving both office-based and central laboratory settings can manage this channel transition more effectively than companies focused on a single testing environment. Product support, result connectivity, staff training, and consistent performance across care settings are becoming increasingly important. Suppliers may also require different commercial offerings, as physician offices prioritize rapid access to defined test menus while central laboratories focus on broader menus, batch efficiency, and automation integration. Clear quality procedures remain essential to ensure confidence in decentralized test results.Regulatory Complexity and Longer Validation Timelines
The IVDR transition increases validation, documentation, and compliance requirements for suppliers of higher-risk diagnostic products in Europe. Class D devices require European Union Reference Laboratory testing before authorization, while Class C devices have later transition deadlines. Compliance with ISO 15189, GDPR, HIPAA, and IEC 62304 raises costs and extends development timelines, favoring established companies with robust quality systems and regulatory capabilities. Smaller developers may face challenges managing documentation, clinical evidence, and post-market obligations, potentially delaying specialized assay availability.Other drivers and restraints analyzed in the detailed report include:
- Increasing Chronic-Disease Testing Intensity
- Antimicrobial Resistance and Infectious-Disease Surveillance
- Reimbursement Pressure and Tender-Based Price Erosion
Segment Analysis
Instruments and Analyzers held 56.45% of the professional diagnostics market share in 2026, supported by multiyear procurement cycles across hospitals and central laboratories. Reagent-rental and subsidized placement models link instrument access to recurring consumable purchases, increasing the long-term value of installed platforms. Platform validation, staff training, workflow redesign, and clinical integration requirements also create switching barriers for laboratories.Reagents and Kits are forecast to grow at a 9.28% CAGR through 2032 as molecular, immunoassay, and flow cytometry systems drive repeat testing demand. Roche is expected to introduce 45 new or updated assays in 2025, expanding menu breadth and reagent demand across its installed base. Software and Informatics remains the smallest category, but laboratory system integration, remote monitoring, and digital support increasingly influence analyzer procurement. Biodesix is expected to expand its Bio-Rad partnership in October 2025 to develop and commercialize in vitro diagnostic assays.
Immunoassay held 44.93% of the professional diagnostics market share in 2026, supported by its use in infectious disease serology, hormone testing, cardiac markers, oncology, and autoimmune panels. Central laboratories and near-patient settings rely on these systems for high-volume routine testing. Molecular Diagnostics is forecast to grow at a 10.12% CAGR through 2032 as next-generation sequencing, multiplex panels, and biomarker-guided testing gain wider adoption.
Clinical Chemistry and Hematology remain essential for standardized, high-volume testing and broad patient coverage. Siemens Healthineers is expected to launch the CN-3000 and CN-6000 hemostasis systems in September 2026, combining clotting, chromogenic, immunoassay, and platelet aggregation testing in a platform up to 60% smaller than alternatives. Microbiology, Flow Cytometry, and Urinalysis continue to serve specialized workflows, while automation and data integration improve processing consistency and reduce manual intervention.
Complete Report Scope:
- By Product Type
- Instruments and Analyzers
- Reagents and Kits
- Software and Informatics
- By Technology
- Immunoassay
- Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Microbiology
- Flow Cytometry
- Urinalysis
- Other Technology
- By Application
- Infectious Diseases
- Oncology
- Diabetes and Metabolic Disorders
- Cardiology
- Autoimmune Diseases
- Neurology
- Nephrology
- Other Application
- By End User
- Hospitals and Clinics
- Diagnostics Laboratories
- Physician Office Laboratories
- Emergency Departments and Intensive-Care Units
- Academic and Research Institutes
- Other End Users
- By Specimen Type
- Blood and Plasma
- Saliva and Oral Fluid
- Urine
- Nasal and Nasopharyngeal Samples
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.78% of the professional diagnostics market share in 2026, supported by high testing intensity, established reimbursement pathways, and a large installed base of immunoassay, molecular, and hematology systems. The region remained a key hub for consolidation in cancer screening and precision oncology diagnostics, with Abbott announcing the acquisition of Exact Sciences for USD 23 billion in November 2025 and BD and Waters announcing the combination of BD’s Biosciences and Diagnostic Solutions business with Waters in July 2025. CLIA classifications and FDA 510(k) pathways remained key compliance requirements, while physician office laboratory expansion continued to shift selected testing volumes to ambulatory settings.Asia-Pacific is forecast to grow at a 9.88% CAGR through 2032, driven by infrastructure investment, a growing middle-income patient population, and broader access to diagnostic services. India is developing cost-competitive diagnostic platforms using microfluidics, biosensors, and AI capabilities, while Sysmex announced a mid-term plan in March 2026 targeting double-digit growth in the Global South and completed the acquisition of JEOL’s BioMajesty clinical chemistry business in April 2026. China’s volume-based procurement model expands testing access but pressures supplier pricing, requiring localized commercial models, product differentiation, and reliable local manufacturing and service capabilities.
Europe is shaped by IVDR requirements, which increase the regulatory burden for manufacturers, while changes to Article 5.5 governance support a more risk-based approach to in-house diagnostics. Gulf states are expanding hospital diagnostic capacity through public health investment, whereas Sub-Saharan Africa relies heavily on infectious disease and antimicrobial resistance programs. In South America, Brazil and Argentina are expanding laboratory networks and government screening programs; however, fragmented registration processes, currency volatility, and tendering pressure create commercial uncertainty. Companies that adapt their test menus and distribution models to local regulatory, funding, and laboratory requirements can better address uneven regional demand.
List of Companies Covered in this Report:
- Abbott Laboratories
- Agilent Technologies
- Beckton Dickinson
- bioMérieux
- Bio-Rad Laboratories
- Bruker
- Danaher
- DiaSorin
- Roche
- Grifols
- Hologic
- Illumina
- QIAGEN
- QuidelOrtho
- Revvity Inc.
- Siemens Healthineers
- Sysmex
- Thermo Fisher Scientific
- Tosoh
- Werfen SA
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Agilent Technologies Inc.
- Becton, Dickinson and Company
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Danaher Corporation
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Grifols SA
- Hologic Inc.
- Illumina Inc.
- QIAGEN NV
- QuidelOrtho Corporation
- Revvity Inc.
- Siemens Healthineers AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Tosoh Corporation
- Werfen SA

